Results of treatment of acute myeloid leukemia in central part of Iran


1 Department of Internal Medicine and Division of Hematology, Isfahan University of Medical Sciences, Isfahan, Iran

2 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Acute myeloid leukemia (AML) is the most common type of leukemia. In this study, outcome of intensive chemotherapy in patients treated in a large urban public university hospital in a developing country was investigated.
Materials and Methods: The records of all patients treated for AML with 3 + 7 protocol from 2002 to 2010 were analyzed.
Results: Among 95 patients, 34 (35.8%) were female and 61 (64.2%) were male patients. Patients' median age was 37 years, ranging 15-68 years. Complete remission (CR) was observed in 56 (58.9%) of patients treated with this protocol. Median overall survival was 13 months (95% CI: 8.8-17.1 months). The 1-year AML survival rate was 51%, and 2-year survival rate was 26%.
Conclusion: Our study shows that in our center in Iran, CR rates and median overall survival rates after induction chemotherapy are less than developed countries.


1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-51.  Back to cited text no. 1
2. Howlader NN, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Available from: http://www.seercancergov/csr/1975_2008/(based on November 2010 SEER data submission, posted to the SEER web site).  Back to cited text no. 2
3. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9.  Back to cited text no. 3
4. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59.  Back to cited text no. 4
5. Flasshove M, Meusers P, Schütte J, Noppeney R, Beelen DW, Sohrab S, et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol 2000;79:533-42.  Back to cited text no. 5
6. Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004;18:989-97.  Back to cited text no. 6
7. Deschler B, Lübbert M. Acute myeloid leukemia: Epidemiology and etiology. Cancer 2006;107:2099-107.  Back to cited text no. 7
8. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010;115:453-74.  Back to cited text no. 8
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.  Back to cited text no. 9
10. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.  Back to cited text no. 10
11. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997;24:57-69.  Back to cited text no. 11
12. Eivazi-Ziaei J. Control of acute myeloid leukemia morbidity in northwest Iran. Asian Pac J Cancer Prev 2005;6:472-3.  Back to cited text no. 12
13. Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:82-101.  Back to cited text no. 13
14. Pulcheri W, Spector N, Nucci M, de Morais JC, Pimenta G, de Oliveira HP. The treatment of acute myeloid leukemia in Brazil: Progress and obstacles. Haematologica 1995;80:130-5.  Back to cited text no. 14
15. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: A report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010;116:5012-21.  Back to cited text no. 15
16. Acute myeloid leukemia. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2012. Available from: [Last cited on 6 Feb 2012].  Back to cited text no. 16
17. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010;116:3147-56.  Back to cited text no. 17